NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab

Adoptive cell therapy and the use of monoclonal antibodies are two therapeutic modalities implemented in the treatment of multiple myeloma (MM). In this study, we combined the anti-CD38 therapeutic mAb daratumumab with different types of NK cells, leveraging the antibody-dependent cell-mediated cyto...

Descrición completa

Detalles Bibliográficos

Principais autores:	David Giraldos, Evelyn Galano-Frutos, Laura Cambronero-Arregui, Manuel Beltrán Visiedo, Eduardo Romanos, Chantal Reina-Ortiz, Gemma Azaceta, Beatriz Martínez-Lázaro, Bárbara Menéndez-Jándula, Alejandro García-Romero, Francisco Javier Jiménez-Albericio, Isabel Marzo, Javier Naval, Alberto Anel
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2025-12-01
Series:	OncoImmunology
Assuntos:	ADCC CD16 daratumumab multiple myeloma NK92
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2559782
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!